| Company Announcements: (reported by the Company) |
No items found
|
| Elevator Pitch: | Lucia Bio is developing highly selective spleen tyrosine kinase (Syk) inhibitors for potential application in peripheral immunology, neurology and haematology oncology. A collaboration between the University of Queensland Emory Drug Discovery Initiative (QEDDI) and Molecule to Medicine (MTM), Lucia Bio is capitalising on QEDDI’s focused discovery and development of oral small molecule inhibitors of Syk, built on the deep knowledge of Syk and dependent pathways. |
| Category: | Health & biotech |
| URL: | https://www.linkedin.com/company/lucia-bio |
| Operational Status: | |
| ASX Listing Code (if applicable): | |
| Year of Commencement: | 2024 |
| Address: | Brisbane, AU |
| State: | Queensland |
| Overseas Operations: | |
| Twitter: | |
| Facebook: | |
| Linkedin: | https://linkedin.com/company/lucia-bio |
| Founders: |
No items found
|
| Awards won: | |
